Literature DB >> 21269281

Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis.

Sylvain Rheims1, Emilio Perucca, Michel Cucherat, Philippe Ryvlin.   

Abstract

PURPOSE: Because of the lack of head-to-head adjunctive-therapy trials of antiepileptic drugs (AEDs) in refractory partial epilepsy, meta-analyses of placebo-controlled randomized controlled trials (RCTs) represent a potentially important source of evidence to guide treatment decisions. However, such indirect comparisons raise various methodologic issues that may hamper their relevance.
METHODS: All RCTs in adult refractory partial epilepsy were analyzed to assess whether efficacy outcomes are influenced by: characteristics of patients and trials ; use of last observation carried forward (LOCF) analysis; evaluation period (entire period versus maintenance period); and year of publication. A meta-analysis of these AEDs was then performed taking these factors into consideration. KEY
FINDINGS: Sixty-three RCTs evaluating 20 AEDs were included. The following variables influenced efficacy estimates: (1) responder rates correlated positively with duration of the entire treatment period (p = 0.038); (2) response to placebo was significantly greater in the maintenance period than in the entire treatment period (p = 0.005); (3) responder rates increased over the years both for AEDs (p < 0.001) and for placebo (p = 0.001); (4) LOCF analysis overestimated responder rates for AEDs (p < 0.001) and for placebo (p = 0.001) compared with completer-based analysis, and the overestimation correlated positively with withdrawal rates (p < 0.001). A meta-analysis of available data showed large differences in efficacy ranking in relation to dose selection and type of analysis, but these were mostly nonsignificant due to statistical power limitations. SIGNIFICANCE: Several methodologic issues hamper the relevance of indirect comparisons of AEDs in the adjunctive-therapy of refractory partial epilepsy. Some of these issues could be overcome by improved standardization in the reporting of efficacy outcomes. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21269281     DOI: 10.1111/j.1528-1167.2010.02915.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  31 in total

1.  The pharmacology of new antiepileptic drugs: does a novel mechanism of action really matter?

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

2.  Meta-analyses of antiepileptic drugs for refractory partial (focal) epilepsy: an observation.

Authors:  Martin J Brodie
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

3.  Confusing placebo effect with natural history in epilepsy: A big data approach.

Authors:  Daniel M Goldenholz; Robert Moss; Jonathan Scott; Sungyoung Auh; William H Theodore
Journal:  Ann Neurol       Date:  2015-07-29       Impact factor: 10.422

4.  AED Trials in Newly Diagnosed Patients: Out With the Old Versus New, in With the New Versus New.

Authors:  Jaqueline A French
Journal:  Epilepsy Curr       Date:  2012-07       Impact factor: 7.500

Review 5.  Characterization of the adverse events profile of placebo-treated patients in randomized controlled trials on drug-resistant focal epilepsies.

Authors:  Fabio Giovannelli; Gaetano Zaccara; Massimo Cincotta; Giulia Loiacono; Alberto Verrotti
Journal:  J Neurol       Date:  2014-10-14       Impact factor: 4.849

Review 6.  Response to placebo in clinical epilepsy trials--Old ideas and new insights.

Authors:  Daniel M Goldenholz; Shira R Goldenholz
Journal:  Epilepsy Res       Date:  2016-02-10       Impact factor: 3.045

7.  Does accounting for seizure frequency variability increase clinical trial power?

Authors:  Daniel M Goldenholz; Shira R Goldenholz; Robert Moss; Jacqueline French; Daniel Lowenstein; Ruben Kuzniecky; Sheryl Haut; Sabrina Cristofaro; Kamil Detyniecki; John Hixson; Philippa Karoly; Mark Cook; Alex Strashny; William H Theodore; Carl Pieper
Journal:  Epilepsy Res       Date:  2017-07-25       Impact factor: 3.045

Review 8.  Lamotrigine XR conversion to monotherapy: first study using a historical control group.

Authors:  Jacqueline A French; Nancy R Temkin; Bassel F Shneker; Anne E Hammer; Paul T Caldwell; John A Messenheimer
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

9.  Investigation of influencing factors on higher placebo response in East Asian versus Western clinical trials for partial epilepsy: a meta-analysis.

Authors:  Yosuke Tachibana; Mamoru Narukawa
Journal:  Clin Drug Investig       Date:  2013-05       Impact factor: 2.859

Review 10.  Do neuroimaging results impact prognosis of epilepsy surgery? A meta-analysis.

Authors:  Zhuo-Ran Yin; Hui-Cong Kang; Wei Wu; Min Wang; Sui-Qiang Zhu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.